{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:37:11Z","timestamp":1794451031877,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Paul C. Zamecnik Chair in Oncology"},{"name":"NCI","award":["K08CA237842"],"award-info":[{"award-number":["K08CA237842"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01093-3","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:43:45Z","timestamp":1758890625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Single-cell RNA-sequencing of BCG na\u00efve and recurrent non-muscle invasive bladder cancer reveals a CD6\/ALCAM-mediated immune-suppressive pathway"],"prefix":"10.1038","volume":"9","author":[{"given":"Ivan","family":"Juric","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Desprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Holton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Almassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Booki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Alban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela H.","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1002\/cncr.28147","volume":"119","author":"K Chamie","year":"2013","unstructured":"Chamie, K. et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer 119, 3219\u20133227 (2013).","journal-title":"Cancer"},{"key":"1093_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-019-0952-y","volume":"20","author":"VT Packiam","year":"2019","unstructured":"Packiam, V. T., Werntz, R. P. & Steinberg, G. D. Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage. Curr. Urol. Rep. 20, 84 (2019).","journal-title":"Curr. Urol. Rep."},{"key":"1093_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","volume":"56","author":"BW van Rhijn","year":"2009","unstructured":"van Rhijn, B. W. et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol. 56, 430\u2013442 (2009).","journal-title":"Eur. Urol."},{"key":"1093_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","volume":"72","author":"EJ Pietzak","year":"2017","unstructured":"Pietzak, E. J. et al. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. Eur. Urol. 72, 952\u2013959 (2017).","journal-title":"Eur. Urol."},{"key":"1093_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog, S. V. et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat. Commun. 12, 2301 (2021).","journal-title":"Nat. Commun."},{"key":"1093_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn4118","volume":"15","author":"FC de Jong","year":"2023","unstructured":"de Jong, F. C. et al. Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guerin. Sci. Transl. Med. 15, eabn4118 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1093_CR7","doi-asserted-by":"publisher","unstructured":"Minoli, M., Kiener, M., Thalmann, G. N., Kruithof-de Julio, M. & Seiler, R. Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. Int. J. Mol. Sci. 21, https:\/\/doi.org\/10.3390\/ijms21165670 (2020).","DOI":"10.3390\/ijms21165670"},{"key":"1093_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"1093_CR9","doi-asserted-by":"publisher","unstructured":"Duex, J. & Theodorescu, D. CD44 in Bladder Cancer. Cancers (Basel) 16 https:\/\/doi.org\/10.3390\/cancers16061195 (2024).","DOI":"10.3390\/cancers16061195"},{"key":"1093_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215935","volume":"551","author":"R Bharti","year":"2022","unstructured":"Bharti, R., Dey, G., Lin, F., Lathia, J. & Reizes, O. CD55 in cancer: Complementing functions in a non-canonical manner. Cancer Lett. 551, 215935 (2022).","journal-title":"Cancer Lett."},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/1535-7163.MCT-21-0823","volume":"21","author":"S Thongchot","year":"2022","unstructured":"Thongchot, S. et al. Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer. Mol. Cancer Ther. 21, 727\u2013739 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"1093_CR12","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.3390\/curroncol29080430","volume":"29","author":"EY Yu","year":"2022","unstructured":"Yu, E. Y. et al. Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study. Curr. Oncol. 29, 5442\u20135456 (2022).","journal-title":"Curr. Oncol."},{"key":"1093_CR13","doi-asserted-by":"publisher","unstructured":"Lodewijk, I. et al. Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring. Int. J. Mol. Sci. 19, https:\/\/doi.org\/10.3390\/ijms19092514 (2018).","DOI":"10.3390\/ijms19092514"},{"key":"1093_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.euo.2020.09.003","volume":"4","author":"C Nicolazzo","year":"2021","unstructured":"Nicolazzo, C., de Berardinis, E. & Gazzaniga, P. Liquid Biopsy for Predicting Bacillus Calmette-Guerin Unresponsiveness in Non-muscle-invasive Bladder Cancer. Eur. Urol. Oncol. 4, 124\u2013125 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.3389\/fimmu.2018.02994","volume":"9","author":"CM Goncalves","year":"2018","unstructured":"Goncalves, C. M., Henriques, S. N., Santos, R. F. & Carmo, A. M. CD6, a Rheostat-Type Signalosome That Tunes T Cell Activation. Front Immunol. 9, 2994 (2018).","journal-title":"Front Immunol."},{"key":"1093_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/eji.201040528","volume":"42","author":"MI Oliveira","year":"2012","unstructured":"Oliveira, M. I. et al. CD6 attenuates early and late signaling events, setting thresholds for T-cell activation. Eur. J. Immunol. 42, 195\u2013205 (2012).","journal-title":"Eur. J. Immunol."},{"key":"1093_CR17","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1084\/jem.20151785","volume":"213","author":"M Orta-Mascaro","year":"2016","unstructured":"Orta-Mascaro, M. et al. CD6 modulates thymocyte selection and peripheral T cell homeostasis. J. Exp. Med 213, 1387\u20131397 (2016).","journal-title":"J. Exp. Med"},{"key":"1093_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00998-x","volume":"20","author":"SN Henriques","year":"2022","unstructured":"Henriques, S. N., Oliveira, L., Santos, R. F. & Carmo, A. M. CD6-mediated inhibition of T cell activation via modulation of Ras. Cell Commun. Signal 20, 184 (2022).","journal-title":"Cell Commun. Signal"},{"key":"1093_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1026521","volume":"9","author":"M Gurrea-Rubio","year":"2022","unstructured":"Gurrea-Rubio, M. & Fox, D. A. The dual role of CD6 as a therapeutic target in cancer and autoimmune disease. Front Med (Lausanne) 9, 1026521 (2022).","journal-title":"Front Med (Lausanne)"},{"key":"1093_CR20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41423-018-0015-1","volume":"15","author":"DA Fox","year":"2018","unstructured":"Fox, D. A. The role of CD6 in autoimmune diseases. Cell Mol. Immunol. 15, 1001\u20131002 (2018).","journal-title":"Cell Mol. Immunol."},{"key":"1093_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1237498","volume":"14","author":"HM Kenney","year":"2023","unstructured":"Kenney, H. M. et al. Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis. Front Immunol. 14, 1237498 (2023).","journal-title":"Front Immunol."},{"key":"1093_CR22","doi-asserted-by":"publisher","unstructured":"Chalmers, S. A. et al. The CD6\/ALCAM pathway promotes lupus nephritis via T cell-mediated responses. J. Clin. Invest. 132, https:\/\/doi.org\/10.1172\/JCI147334 (2022).","DOI":"10.1172\/JCI147334"},{"key":"1093_CR23","doi-asserted-by":"publisher","unstructured":"Ruth, J. H. et al. CD6 is a target for cancer immunotherapy. JCI Insight 6, https:\/\/doi.org\/10.1172\/jci.insight.145662 (2021).","DOI":"10.1172\/jci.insight.145662"},{"key":"1093_CR24","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.3389\/fimmu.2019.03005","volume":"10","author":"G Enyindah-Asonye","year":"2019","unstructured":"Enyindah-Asonye, G. et al. Overexpression of CD6 and PD-1 Identifies Dysfunctional CD8(+) T-Cells During Chronic SIV Infection of Rhesus Macaques. Front Immunol. 10, 3005 (2019).","journal-title":"Front Immunol."},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"M Kates","year":"2020","unstructured":"Kates, M. et al. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin. Cancer Res. 26, 882\u2013891 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1093_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","volume":"78","author":"AG Robertson","year":"2020","unstructured":"Robertson, A. G. et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur. Urol. 78, 533\u2013537 (2020).","journal-title":"Eur. Urol."},{"key":"1093_CR27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","volume":"82","author":"T Strandgaard","year":"2022","unstructured":"Strandgaard, T. et al. Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guerin Failure in Patients with Non-muscle-invasive Bladder Cancer. Eur. Urol. 82, 646\u2013656 (2022).","journal-title":"Eur. Urol."},{"key":"1093_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","volume":"15","author":"C Pettenati","year":"2018","unstructured":"Pettenati, C. & Ingersoll, M. A. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat. Rev. Urol. 15, 615\u2013625 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"1093_CR29","doi-asserted-by":"publisher","unstructured":"Zhang, L. et al. A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders. JCI Insight 8, https:\/\/doi.org\/10.1172\/jci.insight.172914 (2023).","DOI":"10.1172\/jci.insight.172914"},{"key":"1093_CR30","doi-asserted-by":"publisher","unstructured":"Daman, A. W. et al. Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2025.05.002.","DOI":"10.1016\/j.ccell.2025.05.002"},{"key":"1093_CR31","doi-asserted-by":"publisher","first-page":"11385","DOI":"10.18632\/aging.206021","volume":"16","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Integrating single-cell RNA-seq to identify fibroblast-based molecular subtypes for predicting prognosis and therapeutic response in bladder cancer. Aging (Albany NY) 16, 11385\u201311408 (2024).","journal-title":"Aging (Albany NY)"},{"key":"1093_CR32","doi-asserted-by":"publisher","first-page":"11765","DOI":"10.2147\/OTT.S235134","volume":"12","author":"H Lin","year":"2019","unstructured":"Lin, H., Zhou, Q., Wu, W. & Ma, Y. Midkine Is a Potential Urinary Biomarker for Non-Invasive Detection of Bladder Cancer with Microscopic Hematuria. Onco Targets Ther. 12, 11765\u201311775 (2019).","journal-title":"Onco Targets Ther."},{"key":"1093_CR33","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.3892\/ol.2016.5040","volume":"12","author":"D Vu Van","year":"2016","unstructured":"Vu Van, D., Heberling, U., Wirth, M. P. & Fuessel, S. Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer. Oncol. Lett. 12, 3143\u20133152 (2016).","journal-title":"Oncol. Lett."},{"key":"1093_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.801493","volume":"12","author":"K Wu","year":"2021","unstructured":"Wu, K. et al. Targeting TIGIT Inhibits Bladder Cancer Metastasis Through Suppressing IL-32. Front Pharm. 12, 801493 (2021).","journal-title":"Front Pharm."},{"key":"1093_CR35","doi-asserted-by":"publisher","first-page":"21944","DOI":"10.1002\/cam4.6768","volume":"12","author":"ZA Hannouneh","year":"2023","unstructured":"Hannouneh, Z. A. et al. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Cancer Med. 12, 21944\u201321968 (2023).","journal-title":"Cancer Med."},{"key":"1093_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101854","volume":"3","author":"EE Fink","year":"2022","unstructured":"Fink, E. E., Sona, S., Lee, B. H. & Ting, A. H. Processing and cryopreservation of human ureter tissues for single-cell and spatial transcriptomics assays. STAR Protoc. 3, 101854 (2022).","journal-title":"STAR Protoc."},{"key":"1093_CR37","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01093-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:43:46Z","timestamp":1758890626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01093-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01093-3","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}